Entrada's DMD Drug Advances to Higher Dose Cohort 2 in Phase 1/2 Study After Safety Review
TRDA sits 43% above its 52-week low of $4.93.
Summary
An independent Data Monitoring Committee (DMC) recommended Entrada Therapeutics proceed to Cohort 2 of its ELEVATE-45-201 study for ENTR-601-45, increasing the dose to 10 mg/kg from 5 mg/kg. This positive development indicates favorable safety data for the Duchenne muscular dystrophy (DMD) candidate. This news provides a positive clinical update for a key pipeline asset, following a significant stock decline in early May related to detailed data from a different DMD study. The dose escalation recommendation from an independent committee is a strong positive signal for the drug's safety and potential efficacy. The company expects to report Cohort 1 data for ELEVATE-45-201 in mid-2026.
At the time of this announcement, TRDA was trading at $7.06 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $268.3M. The 52-week trading range was $4.93 to $16.45. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.